Istaroxime is under clinical development by Windtree Therapeutics and currently in Phase II for Acute Heart Failure. According to GlobalData, Phase II drugs for Acute Heart Failure have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Istaroxime’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Istaroxime overview

Istaroxime (Debio-0614, PST-2744) is under development for the acute decompensated heart failure and early cardiogenic shock. The drug candidate is administered as intravenous infusion and oral. Istaroxime targets sodium-potassium adenosine triphosphatase (ATPase) with the property of increasing sarcoplasmic reticulum calcium ATPase (SERCA) isoform 2a (SERCA2a) activity.

Windtree Therapeutics overview

Windtree Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing its drug product candidates for the treatment of pulmonary and cardiovascular diseases. The company’s lead development programs are istaroxime, for treating acute decompensated heart failure (ADHF) and cardiogenic shock; Aerosurf, a lucinactant for inhalation, and lyophilized KL4 surfactant intratracheal suspension, both for treating respiratory distress syndrome (RDS) in premature infants; KL4 surfactant for the treatment of lung injury effected by sever Covid-19 infection; oral SERCA2a activators for chronic heart failure; Eleison Oncology for ADS; CVI-IST2 for oral heart failure and rostafuroxin for treating genetically associated hypertension. The company benefits from the proprietary technology platform Aerosol Delivery System (ADS) with pulmonary surfactants or in combination with other products to treat pediatric and adult respiratory disorders. The company operates in Taiwan, Milan, Taipei, and Italy. Windtree Therapeutics is headquartered in Warrington, Pennsylvania, the US.

For a complete picture of Istaroxime’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.